SCHEDULE: State Street Reports Stake in Allogene Therapeutics

State Street Corporation has updated its beneficial ownership filing for Allogene Therapeutics Inc., reporting a 5.5% stake.

Summary

• State Street Corporation has filed a Schedule 13G, indicating its beneficial ownership of Allogene Therapeutics Inc. common stock.
• The filing reports that State Street Corporation beneficially owns 19,025,826 shares of common stock.
• This represents 5.5% of the class of securities.
• The shares are held with shared power to dispose or direct the disposition of 19,025,826 shares.
• The filing also notes shared voting power for 18,772,433 shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily reporting changes in beneficial ownership without disclosing new strategic information or significant financial performance.

Positives

• State Street Corporation's increased or maintained stake may signal confidence in Allogene Therapeutics' long-term prospects.
• The filing provides transparency regarding significant institutional ownership.

Negatives

• The filing does not provide any new financial performance data or strategic updates for Allogene Therapeutics.
• The information is solely related to State Street's ownership, not the operational performance of Allogene.

Risks

• The filing does not explicitly mention any new risks for Allogene Therapeutics.
• However, any significant change in beneficial ownership by a large institution could indirectly impact market perception and stock price volatility.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Allogene Therapeutics.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."
• "After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct."

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine for large institutional investors like State Street Corporation, indicating their holdings in publicly traded companies. This filing confirms State Street's significant, though not controlling, stake in Allogene Therapeutics, a biotechnology company focused on allogeneic CAR T therapies.

Stakeholder Impact

• Shareholders: The filing provides transparency on a significant institutional holder, which can influence investor sentiment. The 5.5% stake by State Street is a notable holding.
• Management: The filing confirms State Street's passive investment approach, not seeking to influence control.
• Market: Increased institutional ownership can sometimes be viewed positively, potentially attracting further investment.

Next Steps

• State Street Corporation will continue to hold and potentially adjust its beneficial ownership of Allogene Therapeutics' common stock.
• Future filings will be made if ownership levels change significantly.

Key Dates

Keywords

Allogene Therapeutics, State Street Corporation, Beneficial Ownership, Schedule 13G, Institutional Investor, Common Stock, Shareholder